Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Krystal Biotech (KRYS) to $224 from $189 and keeps a Buy rating on the shares. The firm, which anticipates Krystal will be able to return to about 50 total new PSF per quarter during Q2, anticipates an equilibrium between efficacy-driven drop in compliance and new patient adds by year-end 2025, the analyst tells investors in a preview.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech price target raised to $255 from $182 at BofA
- Krystal Biotech gets FDA platform technology designation to HSV-1 viral vector
- Krystal Biotech’s Growth Potential Bolstered by FDA Approval and Promising Pipeline Developments
- Buy Rating for Krystal Biotech Driven by Vyjuvek’s Expanded Label and Market Potential
- Krystal Biotech announces FDA approval of update VYJUVEK label